Jeske v. GlaxoSmithKline

• Court: District Court, E.D. Michigan
• Decided: April 11, 2023
• Docket: 1:23-cv-10766
• Status: Unknown

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN NORTHERN DIVISION

JOSEPH A. JESKE AND JAN M. JESKE,

Plaintiffs, Case No. 1:23-cv-10766

v. Honorable Laurie J. Michelson United States District Judge GLAXOSMITHKLINE et al.,

Defendants. ____________________________________/

ORDER TRANSFERRING CASE TO UNITED STATES DISTRICT COURT FOR SOUTHERN DISTRICT OF FLORIDA

Plaintiffs have filed a pro se complaint against 23 companies, incorporating a complaint from another case by reference. ECF No. 1 (incorporating In re Zantac (Ranitidine) Prods. Liab. Litig., No. 9:20-MD-02924 (S.D. Fla. Feb. 20, 2020), ECF No. 31). But the case that Plaintiffs reference is a multidistrict litigation that subsumed their claims. See In re Zantac, 437 F. Supp. 3d 1368 (J.P.M.L. 2020). So the case will be transferred to the Southern District of Florida. See 28 U.S.C. § 1407(a); see also In re Nat’l Prescription Opiate Litig., 956 F.3d 838, 845 (6th Cir. 2020) (“Section 1407 refers to individual ‘actions’ which may be transferred to a single district court, not to any monolithic multidistrict ‘action’ created by transfer.” (quoting Gelboim v. Bank of Am. Corp., 574 U.S. 405, 413 (2015))). Jurisdiction has not been reviewed. Accordingly, it is ORDERED that the Clerk of the Court is DIRECTED to transfer the above-captioned case to the United States District Court for the Southern District of Florida.

Dated: April 11, 2023

s/Laurie J. Michelson LAURIE J. MICHELSON UNITED STATES DISTRICT JUDGE